Relapsed / Refractory
Studies GROUPED
BY:
 TOPIC
SEARCH Drug
Resistance and Lymphoma in ClinicalTrials.gov |
Clinical
Trials for Refractory Lymphoma
Goal: Treating the disease using investigational
therapies or new combinations of
therapies that that may overcome
drug resistance. NOTE: By definition, clinical
trials are investigational, and it is therefore
not known if the
goals of treatments will be realized.
Monoclonal Antibody
Monoclonal
antibodies are man-made antibodies
(proteins) that target receptors on lymphoma cells.
Return to top
.gif) |
*
Condition:
B-cell lymphomas, including CLL
TOPIC SEARCH Mechanisms -
PubMed
TOPIC SEARCH Outcome data -
Medscape |
PubMed
TOPIC SEARCH Safety or Toxicity -
PubMed
|
potential next generation anti-cd20 antibody
|
|
AME-133v
(modified anti-cd20 antibody)
Condition: Relapsed follicular lymphoma, or Refractory cd-20 positive NHL
with "low affinity form of Fc?RIIIa (F/F or F/V at position 158) as determined by FcR genotyping; "
TOPIC SEARCH
Mechanisms - PubMed
|
potential next generation anti-cd20 antibody
|
|
Condition:
- Relapsed or refractory follicular
lymphoma grade I-II
- Tumor verified to be CD20 positive
- CT scan showing demarcated lesions
Rationale and goal: The
purpose of this trial is to determine the safety and efficacy of
HuMax-CD20 as a treatment for
|
Novel Chemotherapy Agents
Monoclonal
antibodies are man-made antibodies (proteins) that target receptors on
lymphoma cells.
Return
to top
novel
chemotherapy agent - similar to anthracyclines
Return
to top
Novel Targeted Agents
Drugs
that target pathways that may have high specificity to Lymphoma cells.
Return
to top
|
|
Btk Inhibitor in Recurrent B Cell Lymphoma
Conditions: Relapsed or
DLBCL (non-GCB subype)
Details:
http://bit.ly/9zOLVV |
Combining novel
chemo and targeted agents
|
|
|
|
|
CD3 immunotoxin
therapy of cutaneous T cell lymphoma
http://bit.ly/b8Wvma
This novel
immunotoxin has dramatic clinical activity even at the
lowest dose in CTCL patients and merits applications at
higher doses in CTCL and other CD3+ T cell leukemia/lymphoma
patients. The lymphodepletion with recovery of T regulatory
cells suggests the drug may be beneficial for
immunosuppression of T cell autoimmune disorders.
Clinical trials:
http://bit.ly/cz7jlZ
|
Return
to top
Novel Immunotherapy
Protocols
experimental
ways to activate the immune system to target Lymphoma cells.
Return
to top
|
|
Wilm's Tumor 1 Protein Vaccine ...
for relapsed NHL after allo SCT
http://bit.ly/cGFFDG
Patients with the blood antigen HLA-A2 and the WT1 cancer
protein who have persistent or recurrent blood cancers after [allo]
stem cell transplantation.
Background: "Most patients [with blood cancers] including NHL
have a protein called Wilm's Tumor 1 (WT1) in their cancer
cells. This protein is thought to be able to influence the
growth of these cancers.
A vaccine made with the WT1 protein may boost the immune system
to help fight these cancers in patients whose cancer cells
contain the protein." |
|
|
|
|
|
|
|
|
Intratumoral
Injection of CPG 7909, Combined With Low dose Local Radiation
NOTE: Study closed as of March 2008, might reopen
before end of year.
Condition: low-grade B-cell lymphoma of any initial
stage or mycosis fungoides of stage IB-IVA. B-cell lymphoma
patients must have failed at least one prior treatment. Mycosis
fungoides patients must have failed or have been intolerant of
at least 2 topical or one systemic treatment.
|
combining radiotherapy with radioimmunotherapy
combining
targeted agents with radioimmunotherapy
utilizing
genetically altered t-cells to target lymphoma cells
utilizing
genetically altered t-cells to target lymphoma cells
novel immune modulating / targeted agent
combines Rituxan
with an immune modulating agent
combines a targeted
agent with rituxan immunotherapy
combines
radioimmunotherapy with monoclonal antibody to treat challenging
CNS lymphoma
combines Rituxan and
Radioimmunotherapy with an immune adjuvant
combines
Radioimmunotherapy with a second agent in T-cell and Hodgkins
lymphomas
adoptive
immunotherapy in EBV-positive lymphomas
Novel Chemo-immunotherapy protocols
Return
to top
Return
to top
Stem Cell Transplant (SCT)-based protocols
Return
to top
utilizing cord blood
for stem cell graft
-
TOPIC SEARCH Cord blood derived Stem Cell transplantation PubMed
standard SCT with
cord blood derived cells
Umbilical
Cord Blood Transplantation
Conditions:
High risk childhood non-Hodgkin's lymphoma;
Graft Versus Host
Disease;
Leukemia;
Lymphoma;
Myelodysplastic (MDS) and
myeloproliferative diseases
utilizing graft
versus lymphoma affect
SCT
Donor
Stem Cell Transplant
Conditions:
Childhood Hodgkin's lymphoma;
Childhood
non-Hodgkin's lymphoma; Leukemia;
Lymphoma; myelodysplastic
and myeloproliferative diseases -
(eligible if relapse from
Auto SCT)
the goal of
treatment is to consolidate SCT with investigational vaccine
therapy
Return
to top
For DLBCL, not eligible or desiring
Stem Cell Transplant (SCT)
Return
to top
Radioimmunotherapy
and Stem Cell Transplant
Return
to top
Radioimmunotherapy as
part of conditioning for Stem Cell Transplantation
|
![PubMed](http://www.google.com/custom?hl=en&lr=&ie=ISO-8859-1&cof=AWFID%3A4452213b291e6613%3BL%3Ahttp%3A%2F%2Fwww.lymphomation.org%2Fimages%2Flymphomation.org.gif%3BLH%3A36%3BLW%3A255%3BBGC%3A%23FFFFFF%3BT%3A%23000000%3BLC%3A%230000CC%3BVLC%3A%230000CC%3BALC%3A%230000CC%3BGALT%3A%23008000%3BGFNT%3A%23000000%3BGIMP%3A%23000000%3BDIV%3A%230000CC%3BLBGC%3A%23FFFFFF%3B&q=site%3Awww.ncbi.nlm.nih.gov+"FcR genotyping"+ antibody" +mechanism&btnG=Search){kind=link}
